- Conditions
- Age-related Macular Degeneration, Neovascular Age-related Macular Degeneration, Wet Macular Degeneration
- Interventions
- bevacizumab, ranibizumab
- Biological
- Lead sponsor
- Outlook Therapeutics, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 228 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 50
- States / cities
- Tucson, Arizona • Arcadia, California • Beverly Hills, California + 46 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 662
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Age-related Macular Degeneration
- Interventions
- Resveratrol, Quercetin, Curcumin (RQC), Curcumin
- Drug
- Lead sponsor
- Paul A Knepper, MD PhD
- Other
- Eligibility
- 50 Years to 90 Years
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Macular Degeneration
- Interventions
- Pazopanib
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 50 Years and older · Male only
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 7
- States / cities
- Beverly Hills, California • Sacramento, California • Winter Haven, Florida + 3 more
- Conditions
- Age-related Macular Degeneration
- Interventions
- Implantable Miniature Telescope (IMT)
- Device
- Lead sponsor
- VisionCare, Inc.
- Industry
- Eligibility
- 65 Years and older
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 14
- States / cities
- Phoenix, Arizona • Irvine, California • Loma Linda, California + 11 more
- Conditions
- Age-Related Macular Degeneration
- Interventions
- Ranibizumab
- Drug
- Lead sponsor
- Retina Center, Minnesota
- Other
- Eligibility
- 55 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Diabetic Retinopathy (DR), Age-related Macular Degeneration (AMD), Mid-peripheral Drusen Formation, Diabetic Macular Edema (DME)
- Interventions
- Photobiomodulation, Ketogenic diet
- Behavioral
- Lead sponsor
- Bristlecone Health, Inc.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Eagan, Minnesota
- Conditions
- Geographic Atrophy
- Interventions
- ACU-4429, Placebo
- Drug
- Lead sponsor
- Kubota Vision Inc.
- Industry
- Eligibility
- 55 Years and older
- Enrollment
- 508 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 1
- States / cities
- Phoenix, Arizona
- Conditions
- Age-Related Macular Degeneration
- Interventions
- Sub-retinal transplantation of MA09-hRPE cells, tacrolimus and mycophenolate mofetil, Placebo tacrolimus and mycophenolate mofetil, Sham Surgery
- Biological · Drug · Procedure
- Lead sponsor
- Astellas Institute for Regenerative Medicine
- Industry
- Eligibility
- 50 Years to 85 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Wet Macular Degeneration
- Interventions
- KSI-301, Aflibercept, Sham Procedure
- Drug · Other
- Lead sponsor
- Kodiak Sciences Inc
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 559 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 59
- States / cities
- Phoenix, Arizona • Springdale, Arkansas • Bakersfield, California + 53 more
- Conditions
- Macular Degeneration
- Interventions
- Ranibizumab
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 225 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 50
- States / cities
- Mesa, Arizona • Phoenix, Arizona • Encino, California + 43 more
- Conditions
- Geographic Atrophy, Macular Degeneration
- Interventions
- JNJ-81201887, Sham Procedure
- Drug · Other
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 60 Years and older
- Enrollment
- 274 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 45
- States / cities
- Tucson, Arizona • Fullerton, California • La Jolla, California + 40 more
- Conditions
- Age-Related Macular Degeneration, Diabetic Retinopathy, Von Hippel-Lindau Syndrome, Retinal Disease, Retinal Vein Occlusion
- Interventions
- Not listed
- Lead sponsor
- National Eye Institute (NEI)
- NIH
- Eligibility
- 2 Years to 120 Years
- Enrollment
- 650 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Started 2012
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Dry Age-related Macular Degeneration
- Interventions
- PRIMA
- Device
- Lead sponsor
- Science Corporation
- Industry
- Eligibility
- 60 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2026
- U.S. locations
- 3
- States / cities
- Palo Alto, California • Miami, Florida • Pittsburgh, Pennsylvania
- Conditions
- Dry Age-related Macular Degeneration, Geographic Atrophy
- Interventions
- ACU-4429, Matching placebo
- Drug
- Lead sponsor
- Kubota Vision Inc.
- Industry
- Eligibility
- Not listed
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 12
- States / cities
- Phoenix, Arizona • Beverly Hills, California • Daytona Beach, Florida + 9 more
- Conditions
- Neovascular Age-Related Macular Degeneration (nAMD)
- Interventions
- 4D-150 IVT (3E10 vg/eye), EYLEA® (aflibercept) Injection 2 mg (0.05mL)
- Biological
- Lead sponsor
- 4D Molecular Therapeutics
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 480 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 54
- States / cities
- Scottsdale, Arizona • Sun City, Arizona • Tucson, Arizona + 49 more
- Conditions
- Dry Age-related Macular Degeneration, Geographic Atrophy
- Interventions
- Surgical implantation of the CPCB-RPE1 implant
- Device
- Lead sponsor
- Regenerative Patch Technologies, LLC
- Industry
- Eligibility
- 55 Years to 90 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2040
- U.S. locations
- 5
- States / cities
- Beverly Hills, California • Huntington Beach, California • Los Angeles, California + 2 more
- Conditions
- Age-related Macular Degeneration, Diabetic Retinopathy, Glaucoma
- Interventions
- Visual acuity (presenting and pinhole), Optical coherence tomography (OCT), Intraocular pressure, Active linkage to care, Fundus Photography
- Other
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 60 Years and older
- Enrollment
- 60,200 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2029
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Retinal Disease, Corneal Disease, Diabetic Retinopathy, Uveitis, Age-Related Macular Degeneration
- Interventions
- Not listed
- Lead sponsor
- National Eye Institute (NEI)
- NIH
- Eligibility
- Not listed
- Enrollment
- 3,833 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1992 – 2015
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Age-Related Macular Degeneration
- Interventions
- 0.5 mg of DE-122, 1.0 mg of DE-122, 2.0 mg of DE-122, 4.0 mg of DE-122
- Drug
- Lead sponsor
- Santen Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 5
- States / cities
- Mountain View, California • Walnut Creek, California • Jackson, Michigan + 2 more
- Conditions
- Geographic Atrophy
- Interventions
- No intervention
- Other
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 296 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 23
- States / cities
- Springdale, Arkansas • Campbell, California • Glendale, California + 19 more
- Conditions
- Exudative Age-Related Macular Degeneration
- Interventions
- Not listed
- Lead sponsor
- The Retina Center of St. Louis County, PC
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2015
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Age-Related Macular Degeneration
- Interventions
- SB11 (Proposed ranibizumab biosimilar), Lucentis (ranibizumab)
- Drug
- Lead sponsor
- Samsung Bioepis Co., Ltd.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 705 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 19
- States / cities
- Poway, California • Colorado Springs, Colorado • Fort Myers, Florida + 16 more
- Conditions
- Age-Related Macular Degeneration
- Interventions
- Fluocinolone Acetonide
- Drug
- Lead sponsor
- Alimera Sciences
- Industry
- Eligibility
- 55 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2008
- U.S. locations
- 1
- States / cities
- Detroit, Michigan
- Conditions
- Neovascular Age-related Macular Degeneration
- Interventions
- AXT107 Low Dose, AXT107 Mid Dose, AXT107 High Dose
- Drug
- Lead sponsor
- AsclepiX Therapeutics, Inc.
- Industry
- Eligibility
- 50 Years to 99 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 4
- States / cities
- Springfield, Massachusetts • St Louis, Missouri • Asheville, North Carolina + 1 more